Mani Mohindru, the Chief Executive Officer of Cardiff Oncology, Inc. (NASDAQ:CRDF), executed a purchase of the company's common stock on June 18, 2026. The acquisition involved 24,703 shares bought at a price of $1.21 each, bringing the total transaction value to $29,890. Following this acquisition, Mr. Mohindru's direct holdings in Cardiff Oncology common stock stand at 24,703 shares.
The timing of this purchase is notable given the stock's recent performance. Cardiff Oncology shares have declined 59% over the past six months and are currently trading near their 52-week low of $1.16. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value estimate of $1.40. Investors seeking deeper insights into Cardiff Oncology's valuation and comprehensive analysis can access the detailed Pro Research Report, available for this and 1,400+ other US equities.
In clinical developments, Cardiff Oncology has reported positive results from its CRDF-004 Phase 2 clinical trial. This trial evaluates onvansertib in combination with standard treatments for first-line RAS-mutated metastatic colorectal cancer. The data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago. The company remains focused on presenting its trial data at this meeting, where it was scheduled for a rapid oral session.
Despite the positive clinical data, Cardiff Oncology is navigating challenges related to a licensing agreement with Nerviano Medical Sciences. Nerviano has terminated a key license agreement for onvansertib, alleging that Cardiff failed to correct inventorship issues related to certain patents. This development has impacted analyst sentiment, with H.C. Wainwright downgrading Cardiff's stock rating from Buy to Neutral, and TD Cowen also downgrading the stock from Buy to Hold due to the ongoing licensing dispute.
To address the updated trial data, Cardiff Oncology announced it will host an investor webcast on June 3, 2026. The webcast aims to provide further insights into the CRDF-004 trial's findings, which are being closely watched by investors and analysts.
Stock performance data shows CRDF closing at 1.21 on June 18, representing a change of +0.030 (+2.54%). Pre-market trading on June 19 shows a price of 1.26, a change of +0.050 (+4.13%). The article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Investors evaluating whether CRDF represents a bargain can utilize the Fair Value calculator, which uses a mix of 17 proven industry valuation models for maximum accuracy. This tool provides the bottom line for CRDF plus thousands of other stocks to help identify potential opportunities.